Doxorubicin is contraindicated in patients with severe hepatic impairment, especially with elevated bilirubin.
Consideration should be given to dose modification for patients with severe increases in transaminases; limited data
exists on the use of doxorubicin in this setting as these patients are routinely excluded from clinical trials.